MedPath

Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.

Not Applicable
Conditions
Hip Osteoarthritis
Blood Loss
Interventions
Registration Number
NCT02085824
Lead Sponsor
Centre of Postgraduate Medical Education
Brief Summary

The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • primary, end-stage hip osteoarthritis requiring total hip arthroplasty
Exclusion Criteria
  • inflammatory arthropathies
  • liver disorders
  • neoplastic conditions
  • clotting disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
enoxaparinEnoxaparinenoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
dabigatrandabigatrandabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
rivaroxabanrivaroxabanrivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
Primary Outcome Measures
NameTimeMethod
Total blood loss by the 3rd postoperative day3rd day postoperatively

Measured for each individual. Measured according to the formula described by Nadler, Hidalgo and Bloch (Prediction of blood volume in normal human adults. Surgery 1962;51:224-32).

Secondary Outcome Measures
NameTimeMethod
Drop in the haemoglobin value between 3rd day postop and preoperative3rd day postopertively

Difference between haemoglobin on the 3rd postopertive day and day before operation

Wound healing disturbances according to the definition of Centers for Disease Control and Prevention3 months postoperatively

Wound healing disturbances - diagnosis to be made according to the definition of Centers for Disease Control and Prevention (Mangram, Horan, Pearson, Silver and Jarvis. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78)

Trial Locations

Locations (1)

Prof. A. Gruca Teaching Hospital, The Medical Centre of Postgraduate Education

🇵🇱

Otwock, Woj. Mazowieckie, Poland

© Copyright 2025. All Rights Reserved by MedPath